Indeed, this seems to make common sense, since the body requires the proper nutritional building blocks to build and repair body tissues, especially those with a high metabolic turnover rate such as skin, hair, and nails
Though it was developed as a diabetes medication, Rybelsus manufacturer, Novo Nordisk, wants the FDA to approve it as a weight loss drug
T2D attenuation
Here is a simple guide: Consider Mounjaro if: You want maximum weight loss results You have both obesity and type 2 diabetes You are comfortable with a higher monthly cost You want faster visible results (noticeable from month 2 in many patients) Consider Ozempic if: Budget is a key consideration You have cardiovascular disease (Ozempic has specific heart-protective approvals) You are starting with a lower dose and want to see how your body responds You prefer a medication with a longer track record globally In both cases, you need: A valid prescription from a qualified doctor Regular monitoring and follow-up consultations A structured diet and lifestyle plan alongside the medication Why Doctor Supervision Matters in India Both Mounjaro and Ozempic are Schedule H prescription drugs in India
After scrapping a Biden-era plan to cover obesity drugs in early 2025, the Trump administration reversed course: it struck deals with Novo Nordisk and Eli Lilly in November 2025 to cut GLP-1 prices, and a voluntary Medicare demonstration begins July 1, 2026 that lets participating drug plans cover GLP-1s for weight loss with a $50 monthly copay
